ImmunoCellular Therapeutics aims to price public sale of equity units

Deal funds clinical trials, research, development, corporate purposes

By Devika Patel

Knoxville, Tenn., June 1 – ImmunoCellular Therapeutics, Ltd. will conduct a public offering of its units with a 45-day greenshoe, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission.

The units will consist of common shares and five-year warrants.

Maxim Group LLC is the bookrunner.

Proceeds will be used for clinical trials, research and development, working capital and general corporate purposes.

ImmunoCellular, based in Los Angeles, develops cellular treatments for brain cancer and neurodegenerative disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.